Cognition Therapeutics price target raised to $6 from $5 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cognition Therapeutics (CGTX) to $6 from $5 and keeps a Buy rating on the shares. The company reported positive top-line results from the Phase 2 SHIMMER trial of its lead candidate, the sigma-2 receptor modulator CT1812, in patients suffering from dementia with Lewy bodies, the analyst tells investors in a research note. The firm added the dementia with Lewy bodies indication to its valuation assessment with a 30% likelihood of approval.